The Indian neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). The key factor that primarily flourishes the growth of the Indian neurological disorder drugs industry includes the rising prevalence of neurological disorders. There is an increased burden of neurological disorders in the country, along with the lack of skilled personnel for the treatment and prescriptions. At the 5th World Heart and Brain Conference held in 2018, it is projected that amongst the 1.36 billion population of India, there were over 30 million people who suffer from neurological disorders, which creates a scope for market growth in the country.

Request a Free Sample of our Indian Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/indian-neurological-disorder-drugs-market

However, there is a lack of neurologists in India as the ratio of one neurologist for more than 1 million population is very low. Along with this, several awareness programs and initiatives regarding neurological disorders may also contribute to the country’s growth in the sector. Besides, the major factor that challenges the growth of the neurological disorder drugs market in India includes the lack of awareness and understanding regarding neurological disorders among the people. Additionally, neurological disorders are also often subjected to various taboos, which heavily impact the lives of patients, and in turn, hampering the neurological disorder treatment market growth in the country.

A full Report of Indian Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/indian-neurological-disorder-drugs-market

Market Coverage

• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Disorder Type
• Country Covered- India
• Competitive Landscape- Novartis International AG, Pfizer Inc., GlaxoSmithKline Plc, Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Cadila Healthcare Ltd.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

India Neurological Disorder Drugs Market – Segmentation

By Disorder Type

• Epilepsy
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Huntington Disease
• Others

Company Profiles

• Alembic Pharmaceuticals Ltd.
• Cadila Healthcare Ltd.
• Cipla Ltd.
• GlaxoSmithKline Plc
• Novartis International AG
• Pfizer Inc.
• Rusan Pharma Ltd.
• Sun Pharmaceutical Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/indian-neurological-disorder-drugs-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404